Noubar is a proven technology pioneer and has dedicated over 30 years of his career to improving the human condition. Under Flagship’s stewardship, Noubar has invested in over 100 bioscience start-ups with an aggregate value of $30 billion by innovating thousands of patents and more than 50 different drugs in clinical development. A former lecturer at MIT’s Sloan School of Management and Harvard Business School, Noubar is a key advocate for how machine learning can help transform sustainable human health.
The next 100 years is likely to become the ‘century of biology’ as the application of machine learning helps biotech companies discover new drugs more quickly and cost effectively. In what Flagship and Noubar term the transition to generative biology, the sophistication of digital science and statistical analysis now means the extraordinary creation and engineering of viruses and entire cells – not just single molecules – is becoming possible.
This is driving significant investment opportunities in early-to-late-stage bioscience as a new frontier in medicine emerges.
ADIA’s access to visionary practitioners informs our investment strategy and portfolio allocation as we seek to generate benchmark-beating returns.
